Huge tail wind in Glaucoma treatment, driving glaucoma treatment CAGR of 28%.   Decline in Cataract based product is masking the growth potential of this business.  

Itrack product will drive 50% of growth in 2019, whilst only representing 20% of revenue.  

2RT technology contributing little revenue, but could be a major catalyst (huge market opportunity), with medical trial results to be released September 30.   

High risk opportunity, but market is missing long term growth potential.